For many people, depression can be successfully managed with medication, counseling, lifestyle changes, or a combination of treatments.
Unfortunately, not everyone responds to these approaches. Some patients continue to experience severe symptoms even after trying multiple therapies. Doctors refer to this condition as treatment-resistant depression.
Treatment-resistant depression can have a major impact on quality of life. People may struggle to work, maintain relationships, or enjoy activities they once loved.
The condition is also associated with a higher risk of hospitalization and other serious mental health challenges. Because of this, finding new treatment options remains a major goal in psychiatry.
One potential option being studied is psilocybin, the active psychedelic ingredient found in certain mushrooms. In recent years, several scientific studies have suggested that psilocybin may produce rapid improvements in depression symptoms when used in a carefully supervised therapeutic setting.
A new study from Switzerland has provided additional evidence that this approach may help some patients. Unlike many previous studies conducted as clinical trials, this research focused on people who received psilocybin treatment in a real-world hospital setting.
Researchers reviewed medical records from 19 patients treated at the Psychiatric University Hospital Zurich. All of the patients had treatment-resistant depression and had not achieved adequate improvement from standard treatments. Depending on their individual treatment plans, patients received between one and four psilocybin sessions.
To evaluate outcomes, the researchers compared depression scores before and after treatment. They used both clinician-rated assessments and questionnaires completed by the patients themselves.
The findings suggested that depression symptoms improved after treatment. Clinician-rated scores fell from an average of approximately 31 out of 60 before treatment to around 20 out of 60 within six weeks after the final session. Patient-reported scores showed a similar pattern, decreasing from about 32 out of 63 to 23 out of 63.
These changes indicate that many participants experienced meaningful reductions in depressive symptoms during the weeks following treatment. Although not every patient improved to the same extent, the overall trend was positive.
The study also examined safety. Side effects occurred during most treatment sessions, but they were generally mild and temporary. Fatigue, headaches, and emotional reactions such as tearfulness were the most commonly reported experiences. Researchers found no evidence of serious or persistent adverse effects in this small group of patients.
Scientists are still trying to understand exactly how psilocybin affects the brain. Current theories suggest that the compound temporarily changes communication patterns between brain regions involved in mood, emotion, and self-reflection. This may help some people process difficult thoughts and emotions in new ways.
Interest in psilocybin research has increased dramatically over the past several years. Researchers around the world are investigating whether psychedelic-assisted therapies could help treat conditions such as depression, anxiety, post-traumatic stress disorder, and addiction.
However, experts stress that these treatments remain experimental in many countries and should not be confused with unsupervised recreational use.
One of the strengths of the Swiss study is that it reflects routine clinical practice rather than idealized research conditions. This provides a glimpse of how psilocybin treatment may perform in everyday healthcare environments.
At the same time, the results appeared somewhat smaller than those reported in some clinical trials, which is common when treatments move from research settings into real-world practice.
The researchers emphasized several limitations. The study involved only 19 patients, which is far too few to provide definitive answers. There was no placebo group for comparison, making it difficult to determine how much of the improvement was directly caused by psilocybin.
The researchers also lacked long-term follow-up data, so they could not determine whether the benefits continued for months or years.
If you care about health, please read studies that scientists find a core feature of depression and this metal in the brain strongly linked to depression.
For more health information, please see recent studies about drug for mental health that may harm the brain, and results showing this therapy more effective than ketamine in treating severe depression.
The study was published in The Lancet Regional Health—Europe.
Source: Psychiatric University Hospital Zurich.
